11 March 2021 - The Department of Health has updated the Public Summary Document for adalimumab (Humira) from the July 2018 PBAC meeting.

This is odd given there is no published outcome for Humira from the November 2020 PBAC meeting.

To make matter worse, the updated Public Summary Document makes no mention of what has been updated.

How can the Department support the call for better/improved transparency in the PBS process, when it does something like this? It needs to set a much better standard here.